Archived documents

Documents past their public comment period for Healthcare & Public Health.

FDAOther

PSG_204096 - Draft Guidance on Tacrolimus

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_050708 - Draft Guidance on Tacrolimus

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_210115 - Draft Guidance on Tacrolimus

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_021395 - Draft Guidance on Tiotropium Bromide

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_203214 - Draft Guidance on Tofacitinib Citrate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_019594 - Draft Guidance on Ursodiol

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_009218-Sol - Draft Guidance on Warfarin Sodium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_009218 - Draft Guidance on Warfarin Sodium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_218785 - Draft Guidance on Zanubrutinib

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

Citizen Petition from Fresenius Kabi USA, LLC

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDAOther

Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry DRAFT GUIDANCE

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDAOther

Topical Dermatologic Corticosteroids In Vivo Bioequivalence - DRAFT Guidance

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →